source
- Sanofi drops pursuit of eczema drug amlitelimab after failed Phase 3 trialsSanofi announced it will no longer seek regulatory approval for amlitelimab, an anti‑OX40 ligand antibody intended for atopic dermatitis, after recent Phase 3 data fell short of expectations. The…
- Scribe Therapeutics upsizes IPO to $128.7 million to fund lipid-lowering gene therapyScribe Therapeutics announced pricing its initial public offering at $128.7 million, surpassing the $96 million target it had set earlier in the week. The company sold 8.6 million shares at $15 ea…